First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Phase 1

Active, not recruiting

• Conditions: EGFR Mutation; HER2 Mutation; Advanced Non-small Cell Lung Cancer
• Interventions: Drug: BAY2927088_formulation A; Drug: BAY2927088_formulation B_1; Drug: BAY2927088_formulation B_2

• Registration Number: NCT05099172
• Lead Sponsor: Bayer

Brief Summary

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to nearby tissues or to other parts of the body.

Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are proteins that help cells to grow and divide. A damage (also called mutation) to the building plans (genes) for these proteins in cancer cells leads to a production of abnormal EGFR and/or HER2. These abnormal proteins drive the growth and the spread of the cancer. Several EGFR and/or HER2 mutations exist in the cancer cells. The study treatment, BAY2927088, is expected to block the mutated EGFR and HER2 proteins which may stop the spread of NSCLC.

The main purpose of this study is to learn:

Escalation, Backfill, and Expansion Part:

* How safe is BAY2927088 for the participants?

* What is the highest dose of BAY2927088 that can be tolerated (maximum tolerated dose) by or given to (maximum administered dose) the participants?

* How does BAY2927088 move into, through, and out of the bodies of the participants?

For this, the researchers will measure the followings:

* The number of participants with medical problems, also called adverse events and serious adverse events, and their severity

* The number of participants who discontinue study treatment due to an adverse event.

* The highest dose of BAY2927088 that the participants can take without having adverse events (maximum tolerated dose (MTD)) or the maximum dose that is tested and found to be safe for the participants in case MTD cannot be found out (maximum administered dose (MAD)) of BAY2927088

* Number of participants experiencing adverse events that prevent an increase in the dose of BAY2927088 (dose-limiting toxicities (DLTs)) at each dose level

* The (average) total level of BAY2927088 in the blood (also called AUC) after receiving single or multiple doses of BAY2927088

* The (average) highest level of BAY2927088 in the blood (also called Cmax) after receiving a single or multiple doses of BAY2927088 Extension Part

* How well does BAY2927088 work in participants?

For this, the researchers will measure the following:

• Percentage of participants whose cancer completely disappears (complete response) or reduces by at least 30% (partial response) after taking the treatment (also known as objective response rate (ORR)). This will be assessed by doctors other than the study doctor.

This study has 4 parts:

* The escalation part aims to find the maximum daily amount (dose) of BAY2927088 that participants can receive.

* The backfill part aims to test the doses of BAY2927088 that are considered safe in the escalation part by giving it to more participants. This will help find optimal doses of BAY2927088 that work well and are safe to be tested in the next part.

* The expansion part aims to determine the dose of BAY2927088 to be tested in further studies.

* The extension part aims to determine whether the selected dose of BAY2927088 from the expansion part works well.

The participants in this study will take the study treatment BAY2927088 in 3-week periods called "cycles". They will in general take BAY2927088 once or twice daily as a liquid/tablet by mouth until their cancer gets worse, they have medical problems, they leave the study, or the study is terminated. Participants will have no more than 5 visits per cycle.

During the study, the study team will:

* take blood and urine samples,

* check the status of the cancer by doing computed tomography (CT) or magnetic resonance imaging (MRI) scans,

* check the participants' overall health and heart health,

* ask the participants questions about how they are feeling and what adverse events they are having.

An adverse event is considered "serious" when it leads to death, puts the participant's life at risk, requires hospitalization, causes disability, causes a baby being born with medical problems, or is medically important.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-10-19
• Study First Submitted QC: 2021-10-19
• Study Start: 2021-10-25
• Study First Posted: 2021-10-29
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-08
• Last Update Posted: 2025-05-13
• Primary Completion: 2025-12-31
• Study Completion: 2026-12-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 370

Inclusion Criteria

• Documented histologically or cytologically confirmed locally advanced NSCLC, not suitable for definitive therapy or recurrent or metastatic NSCLC at screening (small cell or mixed histologies are excluded).
• Documented disease progression after treatment with at least one prior systemic therapy for advanced disease. Participants who do not have standard of care access due to any reason, are intolerant to, or are not eligible for standard treatments, may also be eligible.

Note: Except for participants eligible for one of the groups (Expansion or Extension) who should have received no prior systemic treatment for locally advanced or metastatic disease.

• Adequate archival tumor tissue (ideally taken after last targeted treatment and not older than 6 months) has to be available, either from primary or metastatic sites. If archival material is not available, a fresh tumor biopsy should be performed if feasible and if the procedure poses no significant risk for the participant.

• Measurable disease by RECIST v1.1 with at least one lesion not chosen for biopsy during the screening period (if a biopsy is taken during screening) that can be accurately measured at baseline with computed tomography (CT) or magnetic resonance imaging (MRI) and that is suitable for accurate repeated measurements. A biopsied lesion should not be used as a target lesion for RECIST 1.1 tumor assessments (or, for participants in Expansion Group G, for RANO-BM tumor assessments). Previously irradiated lesions must have shown progression to be considered measurable.

• Documented activating EGFR and/or HER2 mutation assessed by a Clinical Laboratory Improvement Amendments (CLIA)-certified (United States [US] sites) or an equally accredited (outside of the US) local laboratory

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

• Minimum life expectancy of 12 weeks.

• Adequate bone marrow function as assessed by the following laboratory tests to be conducted within 7 days before the first dose of study treatment:

  1. Hemoglobin ≥ 9.0 g/dL. Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within 2 weeks prior to testing.
  2. Platelets ≥ 100 × 10^9 cells/L.
  3. Absolute neutrophil count ≥ 1.5 ×10^9 cells/L. Criteria must be met without the use of hematopoietic growth factors (e.g., G-CSF) within 2 weeks prior to testing.

• Adequate kidney function as assessed by following laboratory test to be conducted within 7 days before the first dose of study treatment:

  a. Estimated glomerular filtration rate (eGFR) > 50 mL/min per 1.73 m^2 according to the Modification of Diet in renal Disease Study Group (MDRD) formula.

• Adequate liver function as assessed by following laboratory tests to be conducted within 7 days before the first dose of study treatment:

  1. Total bilirubin ≤ 1.5 × ULN (or ≤ 3 X ULN for participants with documented Gilbert-Meulengracht Syndrome, or for participants with hyperbilirubinemia considered due to liver metastasis).
  2. Aspartate transaminase and alanine transaminase ≤ 2.5 × ULN (or ≤ 5 × ULN if due to liver involvement by tumor).

Exclusion Criteria

• Treatment with an EGFR tyrosine kinase inhibitor (TKI) ≤ 8 days or 5x the terminal phase, elimination half-lives, whichever is shorter, prior to the first dose of study drug.

• Treatment with a systemic anti-cancer treatment (excluding EGFR TKIs as described above) ≤ 14 days prior to the first dose of study drug.

• Radiation therapy, stereotactic radiosurgery (SRS) and palliative radiation ≤ 14 days prior to the first dose of study drug.

• Treatment with immunotherapy ≤ 28 days prior to the first dose of study drug.

• Have any unresolved toxicity of Grade ≥ 2 from previous anti-cancer treatment, except for alopecia and skin pigmentation. Participants with chronic, but stable Grade 2 toxicities may be allowed to enroll after agreement between the Investigator and Sponsor.

• Any history of primary brain or leptomeningeal disease (symptomatic or asymptomatic), presence of symptomatic central nervous system (CNS) metastases, or CNS metastases that require local treatment (such as radiotherapy or surgery).

• History of spinal cord compression or brain metastases with the following exceptions:

  1. Participants with treated brain metastases that are asymptomatic at screening and who are off or receiving low-dose corticosteroids (≤10 mg prednisone or equivalent) for at least 7 days prior to first dose of BAY 2927088 are eligible to enroll in Dose Escalation and Backfill.

  2. Participants with treated brain metastases that are asymptomatic at screening are eligible in Dose Expansion/Extension (with the exception of Group G) if all of the following criteria are met:

     • there is no evidence of progression (new or enlarging brain metastases) for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period.
     • Participants must be off or receiving low-dose corticosteroids (≤10 mg prednisone or equivalent) for 7 days prior to first dose of BAY2927088.

  3. Participants with history of spinal cord compression >3 months from definitive therapy and stable by imaging (MRI or CT) during the screening period and clinically asymptomatic.

  4. Expansion Group G only: Participants with active (new or progressing) clinically stable brain metastases who do not require immediate CNS-directed treatment as per Investigator's judgement and who are off or receiving low-dose corticosteroids (≤10 mg prednisone or equivalent such as ≤ 1.5 mg/day dexamethasone) in the 7 days prior to first dose of BAY2927088 are eligible.

• History of congestive heart failure (CHF) Class >II according to the New York Heart Association (NYHA) Functional Classification or serious cardiac arrhythmias requiring treatment (e.g. ventricular arrhythmias, atrial fibrillation) or any clinically important abnormalities in rhythm, conduction or morphology or resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval >250 msec)

• Participants with:

  1. Known human immunodeficiency virus (HIV), except as noted below: Participants with history of HIV infection are eligible at the Investigator's discretion provided that: • CD4+ T-cell (CD4+) counts are ≥ 350 cells/uL • The participant has been on established antiretroviral therapy (ART) for at least 4 weeks prior to the start of study drug and has an HIV viral load less than 400 copies/mL prior to start of the study treatment • The ART being used does not contain strong inducers or inhibitors of CYP3A4, and is not anticipated to cause overlapping toxicities with study drug • The participant has not had an opportunistic infection within the past 12 months

  2. Active Hepatitis B infection (positive for Hepatitis B surface antigen [HbsAg]) and Hepatitis B virus [HBV] DNA).

  3. Active Hepatitis C infection (positive anti-HCV Antibody and quantitative HCV RNA results greater than the lower limits of detection of the assay).

     NOTE: Participants with history of chronic HBV or HCV infection are eligible at the Investigator's discretion provided that the disease is stable and sufficiently controlled under treatment.

• Use of strong CYP3A4 inhibitors and inducers from 14 days prior to first administration of study drug. Strong CYP3A4 inhibitors and inducers are prohibited during the study and until Safety FU (follow up) visit.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Dose escalation	BAY2927088_formulation A	Doses of BAY2927088 will be increased in a stepwise fashion up to the MTD or MAD.
Dose escalation	BAY2927088_formulation B_2	Doses of BAY2927088 will be increased in a stepwise fashion up to the MTD or MAD.
Extension part	BAY2927088_formulation B_1	Initiation of the Extension part will depend on the benefit-risk profile observed during Dose Expansion. Additionally, enrollment may be prematurely terminated based on emerging data at the discretion of the Sponsor.
Dose escalation	BAY2927088_formulation B_1	Doses of BAY2927088 will be increased in a stepwise fashion up to the MTD or MAD.
Backfill	BAY2927088_formulation A	Dose Escalation and Backfill run concurrently
Backfill	BAY2927088_formulation B_2	Dose Escalation and Backfill run concurrently
Backfill	BAY2927088_formulation B_1	Dose Escalation and Backfill run concurrently
Dose expansion	BAY2927088_formulation B_1	Eight independent groups (group A, B1, B2, C, D, E, F, G) are planned. Dose Expansion may start at a dose level that has been evaluated in Escalation/Backfill in at least 9 participants and considered safe or at any other dose levels that are below the highest dose level that is considered safe.
Dose expansion	BAY2927088_formulation B_2	Eight independent groups (group A, B1, B2, C, D, E, F, G) are planned. Dose Expansion may start at a dose level that has been evaluated in Escalation/Backfill in at least 9 participants and considered safe or at any other dose levels that are below the highest dose level that is considered safe.
Extension part	BAY2927088_formulation B_2	Initiation of the Extension part will depend on the benefit-risk profile observed during Dose Expansion. Additionally, enrollment may be prematurely terminated based on emerging data at the discretion of the Sponsor.

Primary Outcome Measures

Name	Time	Method
Number of participants with treatment-emergent serious adverse events (TESAEs)	Up to 30 days after the last administration of study treatment
Severity of TEAEs	Up to 30 days after the last administration of study treatment
Maximum tolerated dose (MTD) or maximum administered dose (MAD) of BAY2927088 within the DLT observation period in Dose Escalation (including participants from Backfill qualifying for the MTD population)	At the end of Cycle 1 of a 21-day cycle
Cmax of BAY2927088	Cycle 1, Day 1 (Cycle duration is 21 days)	Cmax: Maximum/peak concentration
Cmax,md of BAY2927088	Cycle 1, Day 15 (Cycle duration is 21 days)	Cmax,md: Cmax after multiple dose administrations
Number of participants with treatment-emergent adverse events (TEAEs)	Up to 30 days after the last administration of study treatment
Severity of TESAEs	Up to 30 days after the last administration of study treatment
AUC(0-24) of BAY2927088 for QD	Cycle 1, Day 1 (Cycle duration is 21 days)	AUC: Area under the concentration vs. time curve. AUC(0-24): AUC from time 0 to 24 hours post dose. QD: Quaque die (once daily)
Number of participants who discontinue study treatment due to an AE	About 4 years (Up to the end of study treatment)
Overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) by blinded independent central review (BICR) in extension part	From the start of the study treatment up to 12 months
Number of participants experiencing dose-limiting toxicities (DLTs) at each dose level associated with administration of BAY2927088 in the DLT observation period in Dose Escalation (including participants from Backfill)	At the end of Cycle 1 of a 21-day cycle	In Dose Escalation (including participants from Backfill)
AUC(0-12) of BAY2927088 for BID	Cycle 1, Day 1 (Cycle duration is 21 days)	If applicable. AUC(0-12): AUC from time 0 to 12 hours post dose. BID: Bis in die, 2 times daily.
AUC(0-24)md of BAY2927088 for QD	Cycle 1, Day 15 (Cycle duration is 21 days)	AUC(0-24)md: AUC(0-24) after multiple dose administrations
AUC(0-12)md of BAY2927088 for BID	Cycle 1, Day 15 (Cycle duration is 21 days)	If applicable AUC(0-12)md: AUC(0-12) after multiple dose administrations

Secondary Outcome Measures

Name	Time	Method
Recommended phase 2 dose (RP2D) of BAY2927088	About 1.5 years
Overall survival (OS) in extension part	From the start of the study treatment up to 12 months
Disease control rate (DCR) per RECIST v1.1 by Investigator assessment and BICR in extension part	From the start of the study treatment up to 12 months
Overall response rate (ORR) as per RECIST v1.1 by investigator assessment	About 4 years	RECIST v1.1: Response Evaluation Criteria in Solid Tumors, version 1.1
ORR per RECIST v1.1 by Investigator assessment in extension part	From the start of the study treatment up to 12 months
Duration of response (DOR) per RECIST 1.1 by Investigator assessment and BICR in extension part	From the start of the study treatment up to 12 months
Progression-free survival (PFS) per RECIST 1.1 by Investigator assessment and BICR in extension part	From the start of the study treatment up to 12 months
Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) categorized by severity in extension part	Up to 30 days after the last administration of study treatment

Trial Locations

Locations (82)

Centro Integral Oncológico Clara Campal; 🇪🇸 Madrid, Spain

Hospital Universitari i Politecnic La Fe | Oncologia; 🇪🇸 Valencia, Spain

Chi-Mei Medical Center, Liouyine; 🇨🇳 Tainan, Taiwan

IPO Porto; 🇵🇹 Porto, Portugal

National Cancer Center Singapore; 🇸🇬 Singapore, Singapore

Curie Oncology | Mount Elizabeth Novena; 🇸🇬 Singapore, Singapore

Ciutat Sanitaria i Universitaria de la Vall d'Hebron; 🇪🇸 Barcelona, Spain

Taichung Veterans General Hospital; 🇨🇳 Taichung, Taiwan

National Cheng Kung University Hospital; 🇨🇳 Tainan, Taiwan

Fundacion Jimenez Diaz (Clinica de la Concepcion); 🇪🇸 Madrid, Spain

National Taiwan University Hospital; 🇨🇳 Taipei, Taiwan

Chang Gung Memorial Hospital at Linkou; 🇨🇳 Taoyuan, Taiwan

UNICANCER - Centre Leon-Berard (CLB) - Medical oncology; 🇫🇷 Lyon Cedex 08, France

West China Hospital Sichuan University; 🇨🇳 Chengdu, Sichuan, China

Banner MD Anderson Cancer Center at Banner Gateway Medical Center; 🇺🇸 Gilbert, Arizona, United States

City of Hope - Duarte Cancer Center; 🇺🇸 Duarte, California, United States

Emory Winship Cancer Institute; 🇺🇸 Atlanta, Georgia, United States

The Center for Cancer and Blood Disorders; 🇺🇸 Bethesda, Maryland, United States

Dana-Farber Cancer Institute; 🇺🇸 Boston, Massachusetts, United States

Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit; 🇺🇸 Detroit, Michigan, United States

NYU Langone Hospital - Long Island - Urology; 🇺🇸 Mineola, New York, United States

Tennessee Oncology; 🇺🇸 Nashville, Tennessee, United States

University of Texas MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States

Virginia Cancer Specialists, PC; 🇺🇸 Fairfax, Virginia, United States

UZ Leuven Gasthuisberg - Pneumology Department; 🇧🇪 Leuven, Vlaams-Brabant, Belgium

AZ Delta | Clinical Trial Center - Pneumology; 🇧🇪 Roeselare, West-Flanders, Belgium

Liga Norte Riograndense Contra o Cancer | Centro de Pesquisa Clínica; 🇧🇷 Natal, Rio Grande Do Norte, Brazil

Hospital de Base | Integrated Research Center; 🇧🇷 São José do Rio Preto, Sao Paulo, Brazil

Hospital Israelita Albert Einstein | Morumbi - Clinical Research Department; 🇧🇷 Sao Paulo, Brazil

Beijing Cancer Hospital; 🇨🇳 Beijing, Beijing, China

Beijing Hospital; 🇨🇳 Beijing, Beijing, China

Fujian Cancer Hospital; 🇨🇳 Fuzhou, Fujian, China

Harbin Medical University Cancer Hospital; 🇨🇳 Harbin, Heilongjiang, China

Union Hospi, Tongji Med College, Huazhong Univ. Scien&Tech; 🇨🇳 Wuhan, Hubei, China

Hunan Cancer Hospital; 🇨🇳 Changsha, Hunan, China

NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School; 🇨🇳 Nanjing, Jiangsu, China

Qilu Hosp., Shandong Univ.; 🇨🇳 Jinan, Shandong, China

Shanghai Chest Hospital, Shanghai Jiaotong University; 🇨🇳 Shanghai, Shanghai, China

Shandong University - Shandong Cancer Hospital; 🇨🇳 Jinan, Sichuan, China

Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine; 🇨🇳 Hangzhou, Zhejiang, China

Zhejiang Cancer Hospital; 🇨🇳 Hangzhou, Zhejiang, China

Zhejiang University School of Medicine - Taizhou Hospital of Zhejiang Province; 🇨🇳 Taizhou, Zhejiang, China

Institut Bergonie - Unicancer Nouvelle Aquitaine - Service Oncologie medicale; 🇫🇷 Bordeaux, France

Hopital Nord Laennec - Oncologie medicale thoracique et digestive; 🇫🇷 Nantes, France

Institut Curie - Paris - Oncologie medicale; 🇫🇷 Paris, France

Institut de Cancerologie Ouest - Saint Herblain - Oncologie medicale; 🇫🇷 Saint Herblain, France

Gustave Roussy - Departement Oncologie-Radiotherapie; 🇫🇷 Villejuif Cedex, France

Prince of Wales Hospital; 🇭🇰 Hong Kong, Hong Kong

Queen Mary Hospital; 🇭🇰 Hong Kong, Hong Kong

Rabin Medical Center | Beilinson Hospital - Internal Medicine C Department; 🇮🇱 Petach Tikva, Israel

Chaim Sheba Medical Center; 🇮🇱 Ramat Gan, Israel

Azienda Ospedaliero Universitaria Parma - SC Oncologia Medica; 🇮🇹 Parma, Emilia-Romagna, Italy

Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati; 🇮🇹 Aviano, Friuli-Venezia Giulia, Italy

Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I; 🇮🇹 Roma, Lazio, Italy

Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1; 🇮🇹 Milano, Lombardia, Italy

Istituto Europeo di Oncologia s.r.l - Sviluppo di nuovi farmaci per Terapie Innovative; 🇮🇹 Milano, Lombardia, Italy

Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia; 🇮🇹 Rozzano, Lombardia, Italy

Azienda Ospedaliero-Universitaria San Luigi Gonzaga - Oncologia Medica; 🇮🇹 Orbassano, Piemonte, Italy

Centro Ricerche Cliniche Di Verona S.r.l. - Oncologia; 🇮🇹 Verona, Italy

Aichi Cancer Center Hospital; 🇯🇵 Nagoya, Aichi, Japan

National Cancer Center Hospital East; 🇯🇵 Kashiwa, Chiba, Japan

National Hospital Organization Shikoku Cancer Center; 🇯🇵 Matsuyama, Ehime, Japan

Hokkaido University Hospital; 🇯🇵 Sapporo, Hokkaido, Japan

Kanagawa Cancer Center; 🇯🇵 Yokohama, Kanagawa, Japan

Osaka International Cancer Institute; 🇯🇵 Osaka-shi, Osaka, Japan

Kindai University Hospital; 🇯🇵 Osakasayama, Osaka, Japan

Shizuoka Cancer Center; 🇯🇵 Sunto, Shizuoka, Japan

National Cancer Center Hospital; 🇯🇵 Chuo-ku, Tokyo, Japan

Tottori University Hospital; 🇯🇵 Yonago, Tottori, Japan

Okayama University Hospital; 🇯🇵 Okayama, Japan

Chungbuk National University Hospital; 🇰🇷 Cheongju-si, Chungcheongbugdo, Korea, Republic of

Seoul National University Bundang Hospital; 🇰🇷 Seongnam-si, Gyeonggido, Korea, Republic of

St.Vincent's Hospital; 🇰🇷 Suwon-si, Gyeonggido, Korea, Republic of

Severance Hospital, Yonsei University Health System; 🇰🇷 Seoul, Seoul Teugbyeolsi, Korea, Republic of

Asan Medical Center; 🇰🇷 Seoul, Seoul Teugbyeolsi, Korea, Republic of

Seoul National University Hospital; 🇰🇷 Seoul, Seoul Teugbyeolsi, Korea, Republic of

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of

Nederlands Kanker Instituut; 🇳🇱 Amsterdam, Netherlands

Erasmus University Medical Center | Research Department - Lung Diseases; 🇳🇱 Rotterdam, Netherlands

National University Hospital Medical Centre; 🇸🇬 Singapore, Singapore

Institut Català d'Oncologia Hospitalet; 🇪🇸 Hospitalet de Llobregat, Barcelona, Spain

Hospital Quiron Dexeus; 🇪🇸 Barcelona, Spain